ArticleAdvanced science (Weinheim, Baden-Wurttemberg, Germany)2026
Advanced Dental Composite Technology via Bisilanized Dual-Action Nanofillers for Biofilm Control.
Article in Advanced science (Weinheim, Baden-Wurttemberg, Germany), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
Abstract
Achieving durable tooth restorations in the complex oral environment demands resin-based composites (RBCs) with long-lasting antibiofilm properties, superior mechanical performance, and biosafety. This study introduces a duomodal strategy to create functional nanofillers for advanced RBC formulations. Mesoporous silica nanoparticles are loaded with the antibacterial agent cetylpyridinium chloride (CPC) and bisilanized using the antibacterial dimethyloctadecyl[3-(trimethoxysilyl)propyl]ammonium chloride (DTSACl) along with 3-(trimethoxysilyl)propyl methacrylate. The resulting bisilanized nanofillers, S_CM, are incorporated into RBCs at various weight percentages (0-20 wt%). The 20 wt% S_CM-RBC formulation showcases exceptional antibiofilm capabilities against 14 oral species, including cariogenic, periopathogenic, and commensal bacteria, leveraging a dual antibacterial mechanism: CPC release and anchored DTSACl action. Additionally, S_CM nanofillers can disrupt bacterial fatty acid metabolism and ATP/nucleotide metabolism. Enhanced mechanical performance is achieved through superior filler-matrix coupling enabled by bisilanization. The formulation demonstrates low water sorption (< 40 µg mm
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.